Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
BioNTech and Genentech elect to end their Phase II trial of autogene Cevumeran after DSMB identified a numerical overall ...
Pharmaceutical Executive: What is the future of field reps and their relationship with AI? Parth Khanna: Based on our ...
Taken together, Hill's response suggests that restricting access through legitimate compounding channels, without addressing ...
Pharma has more competitive data than ever — and is still getting surprised. Lifescience Dynamics on why intelligence requires human judgment. Pharmaceutical companies have never had access to more ...
DualityBio has licensed its Dupac next-generation ADC payload platform to Genentech, and Teva has entered a stalking horse bid to acquire BioXcel's Igalmi. Dealmaking activity spanned oncology and ...
FDA approved Priovant's Lisraya (brepocitinib) as the first targeted therapy for dermatomyositis, Gilead's Bixlenvo as the ...
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical ...
Due the nature of the technology, various companies have implemented it across multiple sectors. Now, the question that everyone is asking is: where is AI having an actual impact? In March of this ...
FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major ...
Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs ...
ACTO CEO Parth Khanna on why sales reps still matter — and how human intelligence plus empathetic agents is the winning formula for field teams.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results